Buy or sell Caribou Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

View More Companies
2021 IPO

Caribou Biosciences Stock

Biotechnology company specializing in genome engineering

Founded

2011

Notable Investors

Anterra Capital

Headquarters

Berkeley CA, US

Total Funding

$74.6M

About Caribou Biosciences Stock

Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.

Investors

Anterra Capital

Caribou Biosciences

Mission Bay Capital

Caribou Biosciences

Pontifax AgTech

fabric, Caribou Biosciences

Funding History

October 2014$2.9M
March 2015$11.5M
May 2016$30.0M
May 2016$30.1M

Management

Co-Founder

Jennifer A. Doudna

Co-Founder

James Berger

Chief Scientific Officer

Andy May

Press

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo